Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (201-210 of 317) with videos related to

Pageof 32
Sort By:
Nature Medicine|February 16, 2021
COVID-19 vaccination: the VOICE for patients with cancerAstrid A M van der Veldt, Sjoukje F Oosting, Anne-Marie C Dingemans, et al.
Journal for Immunotherapy of Cancer|July 21, 2023
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutationElisa A Rozeman, Judith M Versluis, Karolina Sikorska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public WorkshopKristen L Mueller, Marc R Theoret, Steven J Lemery, et al.
The Lancet. Oncology|May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort studyInes Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
British Journal of Cancer|October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysisPrachi Bhave, Lalit Pallan, Georgina V Long, et al.
Cancers|November 26, 2022
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment RegistryDaan Jan Willem Rauwerdink, Remco van Doorn, Jos van der Hage, et al.
Nature Medicine|October 10, 2018
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanomaChristian U Blank, Elisa A Rozeman, Lorenzo F Fanchi, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-upJoost H van den Berg, Bianca Heemskerk, Nienke van Rooij, et al.
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Pageof 32

Showing results (201-210 of 317) with videos related to

Sort By:
Pageof 32
Nature Medicine|February 16, 2021
COVID-19 vaccination: the VOICE for patients with cancerAstrid A M van der Veldt, Sjoukje F Oosting, Anne-Marie C Dingemans, et al.
Journal for Immunotherapy of Cancer|July 21, 2023
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutationElisa A Rozeman, Judith M Versluis, Karolina Sikorska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public WorkshopKristen L Mueller, Marc R Theoret, Steven J Lemery, et al.
The Lancet. Oncology|May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort studyInes Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
British Journal of Cancer|October 22, 2020
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysisPrachi Bhave, Lalit Pallan, Georgina V Long, et al.
Cancers|November 26, 2022
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment RegistryDaan Jan Willem Rauwerdink, Remco van Doorn, Jos van der Hage, et al.
Nature Medicine|October 10, 2018
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanomaChristian U Blank, Elisa A Rozeman, Lorenzo F Fanchi, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-upJoost H van den Berg, Bianca Heemskerk, Nienke van Rooij, et al.
Nature Medicine|February 9, 2021
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Alexander M Menzies, Rodabe N Amaria, Elisa A Rozeman, et al.
Pageof 32